Like TZDs, DPP-4 inhibitors are contraindicated in pregnancy [199]; however, a recent systematic review showed that DPP-4 inhibitors and GLP-1 receptor agonists have the potential to reduce the risk of postpartum T2D and improve β-cell function in patients with GDM [200]. This evidence concerns the gene DPP4 and gestational diabetes.